Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nostrum Pharmaceuticals LLC

www.nostrumpharma.com

Latest From Nostrum Pharmaceuticals LLC

Sun Still Prowling For Acquisitions As It Sells Two US Plants

India's Sun Pharmaceutical Industries has said it is seeking "well-managed" acquisition targets -- unlike its 2015 purchase of troubled rival Ranbaxy which continues to absorb “significant” management time – at the same time as pressing ahead with its consolidation drive with the disposal of two US plants.

BioPharmaceutical Asia Pacific

Sun Sells US Plant As It Tackles Post-Ranbaxy Consolidation

India's Sun Pharma has clinched a deal to sell a US plant as part of a consolidation drive in the wake of its purchase of rival Ranbaxy, amid improving investor sentiment toward the country's biggest drug company.

BioPharmaceutical India

Recent Tech Transfer Deals (01/11)

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public

FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare?
BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Nostrum Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nostrum Pharmaceuticals LLC
  • Senior Management
  • Nirmal Mulye, PhD, Pres.
  • Contact Info
  • Nostrum Pharmaceuticals LLC
    Phone: (732) 543-2440
    1370 Hamilton St.
    Somerset, NJ 08873
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register